Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)

MLA

Christian U. Blank, et al. “Comparable Responses of Melanoma at Primary Site and Synchronous Lymph Node Metastases upon Neoadjuvant Ipilimumab (IPI) and Nivolumab (NIVO).” Annals of Oncology, vol. 30, Oct. 2019, p. v541. EBSCOhost, https://doi.org/10.1093/annonc/mdz255.018.

APA

Christian U. Blank, Georgina V. Long, B.A. van de Wiel, A.C.J. van Akkooi, Judith M. Versluis, Irene L.M. Reijers, Elisa A. Rozeman, Carolien Bierman, & W.J. van Houdt. (2019). Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO). Annals of Oncology, 30, v541. https://doi.org/10.1093/annonc/mdz255.018

Chicago

Christian U. Blank, Georgina V. Long, B.A. van de Wiel, A.C.J. van Akkooi, Judith M. Versluis, Irene L.M. Reijers, Elisa A. Rozeman, Carolien Bierman, and W.J. van Houdt. 2019. “Comparable Responses of Melanoma at Primary Site and Synchronous Lymph Node Metastases upon Neoadjuvant Ipilimumab (IPI) and Nivolumab (NIVO).” Annals of Oncology 30 (October): v541. doi:10.1093/annonc/mdz255.018.